Equities analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report sales of $876.57 million for the current quarter, Zacks reports. Nine analysts have made estimates for Alexion Pharmaceuticals’ earnings, with the highest sales estimate coming in at $900.89 million and the lowest estimate coming in at $847.72 million. Alexion Pharmaceuticals posted sales of $831.00 million in the same quarter last year, which suggests a positive year over year growth rate of 5.5%. The company is expected to issue its next earnings report on Thursday, February 15th.

On average, analysts expect that Alexion Pharmaceuticals will report full-year sales of $876.57 million for the current year, with estimates ranging from $3.49 billion to $3.54 billion. For the next financial year, analysts anticipate that the business will post sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same period last year, the company earned $1.23 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year.

A number of brokerages recently issued reports on ALXN. BidaskClub lowered Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Leerink Swann reissued a “buy” rating and set a $169.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. Evercore ISI began coverage on Alexion Pharmaceuticals in a research note on Wednesday, August 16th. They set an “in-line” rating and a $137.00 price target for the company. BMO Capital Markets reissued an “outperform” rating and set a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, SunTrust Banks reissued a “buy” rating and set a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $154.49.

A number of hedge funds and other institutional investors have recently modified their holdings of ALXN. Fiduciary Trust Co. purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at $111,000. Valeo Financial Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $147,000. Dupont Capital Management Corp purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $156,000. BT Investment Management Ltd purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $165,000. Finally, Penserra Capital Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 144 shares during the period. 94.33% of the stock is owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals (ALXN) opened at $111.90 on Tuesday. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $25,571.46, a P/E ratio of 23.41, a P/E/G ratio of 1.24 and a beta of 1.18.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/12/alexion-pharmaceuticals-inc-alxn-expected-to-announce-quarterly-sales-of-876-57-million.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.